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ABSTRACT
When peripheral neuropathic pain affects a
specific, clearly demarcated area of the body, it
may be described as localized neuropathic pain
(LNP). Examples include postherpetic neuralgia
and painful diabetic neuropathy, as well as
post-surgical and post-traumatic pain. These
conditions may respond to topical treatment,
i.e., pharmaceutical agents acting locally on the
peripheral nervous system, and the topical
route offers advantages over systemic
administration. Notably, only a small fraction
of the dose reaches the systemic circulation,
thereby reducing the risk of systemic adverse
effects, drug–drug interactions and overdose.
From the patient’s perspective, the analgesic
agent is easily applied to the most painful
area(s). The 5% lidocaine-medicated plaster
has been used for several years to treat LNP
and is registered in approximately 50 countries.
Many clinical guidelines recommend this
treatment modality as a first-line option for
treating LNP, particularly in frail and/or elderly
patients and those receiving multiple
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medications, because the benefit-to-risk ratios
are far better than those of systemic analgesics.
However, some guidelines make only a weak
recommendation for its use. This paper
considers the positioning of the 5%
lidocaine-medicated plaster in international
treatment guidelines and how they may be
influenced by the specific criteria used in
developing them, such as the methodology
employed by randomized, placebo-controlled
trials. It then examines the body of evidence
supporting use of the plaster in some prevalent
LNP conditions. Common themes that emerge
from clinical studies are: (1) the excellent
tolerability and safety of the plaster, which
can increase patients’ adherence to treatment,
(2) continued efficacy over long-term
treatment, and (3) significant reduction in the
size of the painful area. On this basis, it is felt
that the 5% lidocaine-medicated plaster should
be more strongly recommended for treating
LNP, either as one component of a multimodal
approach or as monotherapy.
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INTRODUCTION
The 5% lidocaine-medicated plaster has been
used for several years to treat localized
neuropathic pain (LNP) and reviews of
published studies support its use in this
indication [1, 2]. Topical application offers a
number of advantages over systemic
administration. For example, systemic levels of
topical analgesic agents are low—with 5%
lidocaine-medicated plasters, only 3% ± 2% of
the dose reaches the systemic circulation [3] so
the risk of drug–drug interactions, systemic side
effects and overdose is much reduced [4]. This
increased safety margin is important because the
response to prescribed medication can vary
widely between patients, often as a result of
polymorphisms [5], and it is particularly relevant
for vulnerable patients such as the elderly and
those receiving polypharmacy for multiple
co-morbidities. From a practical aspect, the
topical route offers simple site-specific delivery
by the patients themselves to the most painful
areas, without the need for dose titration [6], and
the act of application may increase the placebo
element of analgesia [7].
To date, the 5% lidocaine-medicated
plaster (Versatis, Gru¨nenthal GmbH,
Aachen, Germany) has been registered in
approximately 50 countries around the
world. In the majority of these countries, it
is licensed only for relieving neuropathic pain
caused by postherpetic neuralgia (PHN), but
in 11 Latin American countries it has been
approved for treating LNP. The total
cumulative patient exposure to 5%
lidocaine-medicated plaster since marketing
authorization was first obtained in 1999 has
now reached approximately 23 million
patients. Its efficacy and safety in treating
PHN have led to widespread use in other LNP
syndromes, including diabetic distal
polyneuropathy, post-surgical, and
post-traumatic pain [1].
A number of researchers and reviewers have
recommended the lidocaine plaster as a
first-line option for treating LNP [2, 8–15],
because the benefit-to-risk ratios are far better
than those of systemic analgesic agents [16, 17].
At the present time, the management of
patients with neuropathic pain is often
inadequate [18, 19], and many patients are not
satisfied with their treatment [20, 21]. The
objective of this article is to examine the
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inclusion of the 5% lidocaine-medicated plaster
in international treatment guidelines and the
body of evidence currently supporting its use, so
that this pharmacological option may be
considered more often by clinicians treating
patients with LNP.
Compliance with Ethics Guidelines
This article is based on previously conducted
studies and does not involve any new studies of




Lidocaine is a voltage-gated sodium channel
inhibitor, which is understood to act by
blocking abnormally functioning (sensitized)
Nav1.7 and Nav1.8 sodium channels in the
dermal nociceptors of A delta and C fibers,
thereby reducing the number of ectopic
discharges [22–24]. However, it is also effective
in patients where nociceptive function is
impaired [25]. This is probably due to an
inhibitory effect on inflammatory processes, as
lidocaine has been shown to regulate T cell
activity and suppress the production of nitric
oxide [26, 27]. Another probable mechanism is
direct activation of the TRP (transient receptor
potential) channels TRPV1 and TRPA1
expressed in nociceptive sensory neurons. This
produces analgesia by membrane
depolarization, reducing the electrical activity
in TRP-containing nerves [28].
Each 5% lidocaine-medicated plaster
measures 10 9 14 cm and consists of a white
hydrogel adhesive containing lidocaine
(700 mg, 5% w/w) attached to a non-woven
polyethylene terephthalate backing [29]. The
plaster is applied once daily to intact, dry,
non-irritated skin and worn for a maximum of
12 h. Up to three plasters may be applied
simultaneously, depending upon the size of
the painful area, and the subsequent plaster-free
period must be at least 12 h [29]. Where
appropriate, plasters may be cut to match the
shape of the painful area. Application provides
mechanical protection and a sensation of
immediate cooling (the ‘patch’ effect) [30].
Steady-state plasma concentrations of
lidocaine are reached within the first 4 days
[29], but the maximum concentration remains
far below clinically relevant levels even when
the recommended dose is exceeded [31]. After
extensive metabolism in the liver, mainly by
N-alkylation, the excretion of lidocaine and its
metabolites is primarily via the kidneys [29].
Less than 10% of the lidocaine dose is excreted
unchanged [29]. The elimination half-life in
healthy individuals is 7.6 h, but may be delayed
in the presence of cardiac, renal, or hepatic
insufficiency [29]. Treatment should be
reassessed at regular intervals to determine
whether the number of plasters can be
reduced, or the plaster-free period extended
[29].
Treatment with the lidocaine plaster is
generally well tolerated and markedly
improves patients’ quality of life [1]. The most
frequently reported adverse events are
mild-to-moderate reactions at the application
site, including erythema, pruritus, rash, burning
sensation, edema, and other skin reactions
[9, 17, 32]. These adverse events are generally
transient and resolve without further treatment
once the plaster is removed [17]. Furthermore,
the excellent safety profile continues with
long-term treatment. In an open-label study
lasting up to 4 years, medication was rated as
‘good’ or better by 88% of patients and only
18.6% experienced adverse events that could be
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related to their treatment [33]. Another group of
patients with chronic refractory neuropathic
pain caused by postherpetic neuralgia was
surveyed after using the lidocaine plaster daily
for a mean period of 7.6 years [34]. Using an
11-point numerical rating scale (NRS) on which
a score of ?5 represented ‘Extremely Satisfied’
and -5 ‘Extremely Dissatisfied’, mean
satisfaction with pain relief was rated at ?3.8,
mean overall satisfaction at ?4.0, and 75% of
the patients reported having had no adverse
events [34].
NEUROPATHIC PAIN AND LNP
Neuropathic pain is defined by the
International Association for the Study of Pain
(IASP) as ‘‘pain arising as a direct consequence
of a lesion or disease affecting the
somatosensory system’’ [35, 36].
Population-based surveys in the United
Kingdom and France have found the
prevalence of pain with predominantly
neuropathic characteristics to be 8% and 6.9%,
respectively [37, 38]. Currently, expert opinion
is that neuropathic pain arises from damage to
somatosensory small fibers rather than
non-nociceptive pathways [39, 40]. The origin
may be central or peripheral, and neuropathic
pain is a feature of many different conditions.
The most common symptoms are continuous
burning pain, paroxysmal ‘electric shock’ or
lancinating pain, and allodynia [40–42].
Burning pain reflects spontaneous
hyperactivity in nociceptive C-fiber pathways,
which may originate from (1) ‘irritable’
nociceptors (i.e., that have increased
excitability as a result of peripheral
sensitization, mainly produced by changes in
voltage-gated sodium channel expression [43]),
(2) hyperexcitable regenerating nerve sprouts,
or (3) denervated central neurons [40].
Paroxysmal pain probably arises from
high-frequency ectopic bursts generated in
demyelinated, non-nociceptive Ab fibers [40].
Mechanical dynamic allodynia is mediated by
non-nociceptive Ab fibers activating central
pain pathways, but ‘irritable’ C-nociceptors
probably contribute to the maintenance of
allodynia and to central sensitization in
peripheral neuropathies [40].
Evidence suggests that herpes zoster and
peripheral nerve traumas are the most
frequent causes of peripheral neuropathic
pain, whereas stroke, multiple sclerosis and
spinal cord injury are the major causes of
central neuropathic pain [44–47]. The negative
impact upon functioning and quality of life is
profound [48, 49]. Studies have demonstrated
that neuropathic pain is more severe than
non-neuropathic pain [50], it is associated
with an excessive psychosocial burden
compared with nociceptive pain, and it can
induce more intense psychological comorbidity
than other types of chronic pain [48, 50, 51].
Although neuropathic pain may be widely
distributed, in approximately 60% of patients it
affects a specific, clearly demarcated area of the
body [52] and may be described as ‘localized
neuropathic pain’ (LNP). In order to help
clinicians distinguish LNP from other types of
neuropathic pain, a body of experts proposed
the following definition of LNP in 2010, based
upon the IASP definition of neuropathic pain
and 13 reference articles: ‘A type of peripheral
neuropathic pain that is characterized by
consistent and circumscribed area(s) of
maximum pain associated with abnormal
sensitivity of the skin and/or spontaneous
symptoms characteristic of neuropathic pain,
for example, burning pain’ [52]. By identifying
patients with LNP—who may benefit from
topical treatment—this definition facilitates an
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evidence-based approach to the management of
neuropathic pain. It should be pointed out that
topical treatment refers to pharmaceutical
agents that act locally on the peripheral
nervous system, in contradistinction to
medications such as buprenorphine and
fentanyl that may be applied to the skin but
which exert their effect on the CNS following





Most clinical evidence on the efficacy of the 5%
lidocaine-medicated plaster—and most
guidelines—relate to the treatment of PHN,
owing to its being more widely licensed for
this condition, and the comparatively recent
definition of LNP.
For its 2004 guidelines, reaffirmed in 2010,
the Quality Standards Subcommittee of the
American Academy of Neurology examined 51
articles on therapies for treating PHN [53]. The
following parameters were calculated for each
study using intent-to-treat analysis: absolute
risk reduction (proportion of control group
with benefit minus proportion of treated
group with benefit); number needed to treat
(NNT) for adequate pain relief; 95% confidence
interval for the NNT; and number needed to
harm (NNH). A score was then determined for
each therapy based upon the quality of the
studies (e.g., Class I evidence was provided by a
prospective, randomized, controlled clinical
trial with masked outcome assessment in a
representative population). On the basis of
these criteria, the 5% lidocaine-medicated
plaster was placed in the top treatment
category for PHN, along with gabapentin,
oxycodone or morphine sulphate, pregabalin
and tricyclic antidepressants (TCAs) [53]. These
were all considered to offer medium-to-high
efficacy, good strength of evidence supporting
their use, and a low level of side effects [53].
Evidence-based recommendations for the
treatment of neuropathic pain were first
published by the Neuropathic Pain Special
Interest Group (NeuPSIG) of the IASP in 2007,
following a consensus meeting [8]. Initially,
relevant publications were identified through
Medline literature searches (1966–2007),
reference lists of published articles and book
chapters, and personal knowledge of the
authors. This published material, along with
unpublished data and the authors’ clinical
experience, was then used to evaluate various
medications in terms of efficacy, safety,
tolerability, drug interactions, ease of use, and
impact on health-related quality of life [8].
Having demonstrated efficacy in PHN and
diverse peripheral neuropathic pain
conditions, the 5% lidocaine-medicated plaster
was recommended as a first-line treatment for
peripheral neuropathic pain, but not for central
neuropathic pain [8]. These recommendations
were later reviewed and updated by NeuPSIG in
2010, after more clinical trials had been
completed [11]. Group members concluded
that adherence to the existing guidelines
should be improved for the time being, while
additional randomized, controlled trials directly
comparing neuropathic pain medications were
conducted and alternative evaluative strategies
were developed [11].
Later in 2010, recommendations on the
pharmacological management of neuropathic
pain were published by Attal et al. [54]. These
recommended topical lidocaine as a first-line
treatment for PHN, commenting on its
excellent tolerability and noting that all
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recommendations for the pharmacological
treatment of neuropathic pain at that time
proposed antiepileptics (gabapentin or
pregabalin), TCAs, serotonin–noradrenaline
reuptake inhibitors (SNRIs) or topical lidocaine
as the first line of treatment for neuropathic
pain in general, or for specific neuropathic pain
conditions [54].
Narrower terms of reference were used by the
European Federation of Neurological Societies
(EFNS) Task Force to produce its guidelines,
which were first published in 2006 [55] and
updated in 2010 [13]. The Cochrane Database
and then Medline were searched for relevant
studies, which were subsequently classified
according to the etiological condition
investigated. All EFNS Class I and Class II
randomized controlled trials were assessed,
with lower class studies being considered in
conditions for which there were no top level
studies. NNT values and their corresponding
95% confidence intervals were calculated in
order to provide information about the overall
efficacy of analgesic agents [13, 55]. The earlier
guidelines considered that there was
insufficient evidence to confirm the efficacy of
the lidocaine plaster, but stated that it may be
preferred to other agents when treating
PHN–particularly in patients with allodynia
and a small area of pain—because of its
excellent tolerability [55]. The inclusion of
additional trials in the 2010 update provided
some good evidence of efficacy, although trial
results were inconsistent. Consequently, the
updated guidelines stated that the 5%
lidocaine-medicated plaster may be considered
a first-line treatment in the elderly, particularly
if there are concerns regarding the CNS side
effects of oral medications [13].
A new, more rigorous and generally accepted
methodology (GRADE—Grading of
Recommendations Assessment, Development,
and Evaluation) was adopted for the 2015
revision of the NeuPSIG guidelines [56].
GRADE classifies the quality of evidence as
high, moderate, or low according to various
factors, including the risk of bias, precision of
estimates, consistency of results, and directness
of evidence [57]. A strong recommendation for
use is given only when the benefits of an
intervention clearly outweigh the undesirable
effects [57]. A systematic review and
meta-analysis were conducted of randomized,
double-blind studies of pharmacotherapy for
neuropathic pain, as well as unpublished trials
retrieved from ClinicalTrials.gov and the Web
sites of pharmaceutical companies [56]. The
NNT for 50% pain relief was used as the primary
outcome measure, and publication bias was
assessed. Stringency of the GRADE criteria
meant that only three trials of the lidocaine
plaster were included, so that the quality of
assessed evidence was low. Thus, only a weak
recommendation for use was made, as a
second-line treatment for peripheral
neuropathic pain with presumed local pain
generator (such as PHN), post-traumatic
painful neuropathies and polyneuropathies
[56]. However, it was acknowledged that in
certain circumstances, such as concern about
side effects or the safety of first-line options,
particularly in frail and elderly patients, the 5%
lidocaine-medicated plaster might be a first-line
option [56].
Also in 2015, an international advisory board
of pain specialists, selected on the basis of their
research activity and considerable clinical
experience, met to develop a treatment
guidance algorithm specifically for LNP, to be
used in the primary care setting [15]. It was
generally felt that existing guidelines were of
limited use in determining treatment for LNP,
because most do not specifically address this
condition—or even recognize it as a specific
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entity—and recommendations of the different
guidelines are not consistent [15]. Board
members strongly agreed that the first-line
treatment—irrespective of age—should be a
topical analgesic agent in most cases unless
there are contraindications such as broken,
atrophic, or infected skin—essentially because
the topical route offers a far better safety profile
[16, 17] and there is evidence that it can reduce
the size of the painful area [58–60]. Factors
influencing the choice of topical agent should
include ease of application and use, patient
preference, and availability [15], but the 5%
lidocaine-medicated plaster currently has the
most evidence supporting its use in treating
LNP.
SUPPORTING EVIDENCE
IN THE TREATMENT OF LNP
Postherpetic Neuralgia (PHN)-Efficacy
PHN is a common complication of herpes zoster
infection or ‘shingles’, which may persist for
months or even years. Patients experience
persistent pain, often intense, which has been
described as burning, stabbing, shooting, or
throbbing. Tactile allodynia (pain evoked by
lightly touching the skin) is present in C70% of
patients [61]. This symptom is associated with
significant loss of function and reduced quality
of life, particularly in the elderly, and is highly
resistant to treatment [62, 63]. Although the
number of randomized, controlled studies is
limited, the efficacy of the 5%
lidocaine-medicated plaster in PHN treatment
has been demonstrated in many open-label
studies and case series, and is well established
[1, 2].
A 2009 paper by Garnock-Jones and Keating
reviewed the clinical evidence for using the
lidocaine plaster to treat PHN, focusing on fully
published studies [9]. Two randomized,
double-blind, placebo-controlled trials had an
initial open-label phase before responders were
randomized to comparative treatment for a
period of up to 2 weeks [64, 65]. The primary
endpoint was the time to exit from treatment as
a result of lack of efficacy, defined as a drop of
C 2 points on the Visual Rating Scale (VRS) of
pain relief from baseline [64, 65]. In one study,
the time to exit was significantly different
between the groups for the intention-to-treat
(ITT) population ([14 days for lidocaine vs.
3.8 days for placebo; p\0.001) [64]. In the
other study, this difference did not reach
significance in the ITT population, but did in
the per-protocol (PP) population (14.0 vs.
6.0 days; p\0.0398) [65]. When compared to
pregabalin in a 4-week, open-label, randomized,
non-inferiority study, more patients with PHN
in the PP population responded to topical
lidocaine than to pregabalin capsules (62.2 vs.
46.5%), and also experienced a more marked
reduction in ‘painful’ and ‘extremely painful’
allodynia (58% at baseline to 25% at endpoint
vs. 63% at baseline to 41% at endpoint) [16]. In
addition, the consumption of rescue medicine
was reduced by half in the patients treated with
topical lidocaine, but no change was observed
in those receiving pregabalin [66]. The authors
of the review paper concluded that the 5%
lidocaine-medicated plaster is a useful first-line
option for treating patients with PHN [9].
A 2011 systematic review compared the 5%
lidocaine-medicated plaster for the relief of PHN
with other relevant interventions and placebo
[67]. Six databases were searched up to May
2010 and a network meta-analysis conducted.
When multiple interventions are used for the
same disease and outcomes, this technique
employs indirect evidence to gain certainty
about all treatment comparisons, thereby
Pain Ther (2016) 5:149–169 155
allowing parameters such as efficacy and
safety—which have not been investigated in
head to head clinical trials—to be compared
[68]. This network meta-analysis included 20
unique studies (32 publications). The results
suggest that the 5% lidocaine-medicated plaster
and gabapentin provide similar levels of pain
relief and, furthermore, that the lidocaine
plaster is more effective than pregabalin or
high-dosage topical capsaicin [67].
An open-label, Phase III study carried out in
12 European countries assessed the efficacy of
the lidocaine plaster over a period of up to
4 years [33]. Patients aged[50 years with PHN
lasting C 3 months and a baseline pain intensity
of at least 4 on an 11-point NRS (0–10) received
the lidocaine plaster in addition to any existing
medication. Pain relief was measured using a
six-point VRS (1 = worse pain to 6 = complete
relief) according to each patient’s recollection
of pain intensity over the previous week. A
mean pain relief score of 4.3 was achieved after
6 weeks of treatment with the 5%
lidocaine-medicated plaster—equivalent to
between ‘moderate’ and ‘a lot’ on the VRS—
and this level was maintained throughout the
1-year main study and the 3-year extension
phase [33]. The Patient Global Impression of
Change (PGIC) was assessed during the
extension phase; the proportion of patients
rating it as ‘much improved’ or ‘very much
improved’ was 71% at 24 months and 93% at
36 months [33].
A recent study by Casale et al. comprised a
case series of elderly patients with PHN who
were receiving one or more systemic drugs, but
whose pain was inadequately controlled or who
had good pain control but were experiencing
severe side effects [60]. The 5% medicated
plaster was prescribed in addition to their
systemic medication and they were followed
up for 3 months. Effective pain relief began as
early as 2 weeks after the commencement of
topical treatment and steadily increased,
reaching 52.00 ± 23.87% after 4 weeks and
60.00 ± 18.70% after 12 weeks [60]. Notably,
the area of allodynia progressively decreased
from baseline, with a reduction of 46% after
1 month (p = 0.129) and 66% after 3 months
(p = 0.02), enabling patients to apply fewer and
smaller plasters [60]. The authors suggest these
results indicate a possible role for long-term
treatment with the lidocaine plaster to reduce
the painful area affected by LNP, although
further research is needed [60].
Postherpetic Neuralgia (PHN)-Safety
The incidence of PHN increases with age and is
uncommon in patients younger than 60 years
[69]. Many are already being treated for
co-morbidities with a variety of medications,
so minimizing the risk of adverse events for
these patients is particularly important. The 5%
lidocaine-medicated plaster is the only PHN
treatment for which safety and efficacy data on
clinical use of up to 4 years duration is available
[17, 33].
In a prospective, open-label,
non-randomized study in 332 patients with
PHN, there were no serious systemic ADRs,
and no ADRs relating to an organ class other
than the skin affected more than 10% of the
patients [70]. In a comparison study with
pregabalin by Baron et al., five patients in the
lidocaine group reported five ADRs, of which
three were mild or moderate application-site
reactions [16]. By contrast, 25 patients in the
pregabalin group reported 82 ADRs, and 22 of
these were of severe intensity [16].
The safety and tolerability of this treatment
has been summarized in a recent review of both
published material and unpublished clinical
data [17]. In a pooled analysis of three clinical
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trials that included 394 subjects with a mean
age of [70 years, 78 patients experienced 131
ADRs [17]. None was considered to be serious
and 83% were related to the skin, with
application site erythema and pruritus being
reported most frequently [17]. A separate study
in elderly patients with PHN (mean age
70 years) found that cognitive integrity was
maintained in those treated with the 5%
lidocaine-medicated plaster, whereas those
receiving systemic medication were
significantly impaired in terms of vigilance,
decision-making, and semantic memory [71].
For most studies, the rate of premature
discontinuation of treatment with the
lidocaine plaster because of ADRs is less than
5% [17]. Post-marketing experience has revealed
that more serious reactions such as open
wounds, hypersensitivity, and anaphylactic
shock do occur, but are extremely rare (\1/
10,000 patients) [29].
Painful Diabetic Neuropathy (DN)
Diabetic polyneuropathy is the most common
complication of type 1 and type 2 diabetes
mellitus, affecting as many as 50% of patients
[72]. It typically manifests as ‘burning’ pain
associated with paraesthesia/dysesthesia and/or
allodynia [73]. The effect on physical and
mental quality of life is profound, even after
adjusting for pain intensity, yet one survey
found that only 28% of diabetic patients with
neuropathic pain were receiving a treatment
recommended for it [73].
When the 5% lidocaine-medicated plaster
was added to existing treatment for DN in an
open-label study, it was shown to produce
significant improvements in Brief Pain
Inventory (BPI) scores for pain intensity and
pain relief after 2 weeks (Table 1) [74]. These
were accompanied by significant reductions of
pain interference with general activity, mood,
walking ability, normal work, relationships with
others, sleep, and enjoyment of life [74]. In
another study, the treatment effect was
evaluated according to changes in four
composite measures of the Neuropathic Pain
Scale (NPS-10, NPS-4, NPS-8, and
NPS-non-allodynia) over a period of 2 weeks
(Table 1) [75]. Adding the lidocaine plaster
significantly improved all four composite
measures (p\0.001) and was well tolerated,
with no reports of serious adverse events or
adverse drug interactions [75].
The 5% lidocaine-medicated plaster was used
as monotherapy in the comparative study with
pregabalin previouslymentioned, and results for
the diabetic polyneuropathy population
(Table 1) differed slightly from those for PHN
patients [16]. The response rates to treatment
(defined as a reduction of C2 from baseline or an
absolute score of B4 on the NRS in the PP
population at the end of the treatment period)
were similar in the lidocaine and pregabalin
groups (67vs. 69%, respectively) [16]. Reductions
in the severity of allodyniawere also comparable,
but the EuroQol-5 Dimension (EQ-5D) quality of
life index showed a greater improvement in the
lidocaine group (0.13 ± 0.2) than in the
pregabalin group (0.06 ± 0.2) [16].
A 2010 systematic review specifically
investigated the role of the 5%
lidocaine-medicated plaster in painful diabetic
peripheral neuropathy [12]. Six databases were
searched and 23 studies (38 publications) were
included. In order to compare the lidocaine
plaster with other relevant treatments for which
direct comparative studies were not available,
quantitative methods for data synthesis were
used and a network meta-analysis conducted
[12]. The results showed that all the
interventions examined (5%
lidocaine-medicated plaster, amitriptyline,
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capsaicin, gabapentin, pregabalin) were more
effective than placebo, and the effects of the
lidocaine plaster on pain were comparable to all
the other interventions [12]. In addition, the
results suggest that topical treatments are
associated with fewer and less clinically
significant adverse events than systemic agents
[12]. The authors concluded that in view of its
comparable efficacy and greater tolerability, the
5% lidocaine-medicated plaster should be
considered as a first-line treatment for diabetic
peripheral neuropathy, but the small numbers,
limited size, and quality of the studies in their
review should be taken into account [12].
Post-Surgical/Post-Traumatic/Scar Pain
Acute postoperative pain is due to the surgical
lesion, but in 10–50% of cases, depending upon
the specific surgical procedure, the pain persists
[76, 77]. Chronic post-surgical pain usually has
a neuropathic component, as a result of focal
nerve damage at or around the surgical scar, and
it has a considerable impact on the patient’s
quality of life [76]. Trauma often results in
chronic post-traumatic pain as a result of nerve
damage at the site of the injury [78]. In both of
these conditions, the patient experiences
intense pain in the innervation area of the
affected peripheral nerve, which may persist for
a long time and radiate to other remote sites.
Additional symptoms can include allodynia,
hyperalgesia, numbness, and paraesthesia.
Efficacy of the 5% medicated plaster in
treating acute post-surgical pain was
demonstrated in the prospective study by
Habib et al. [79] (see Table 2). Over the 24 h
following radical retropubic prostatectomy,
Table 1 Studies involving use of the 5% medicated plaster to treat painful diabetic neuropathy










Main efﬁcacy outcomes (end of
observation)
White et al. [74]. Open-label pilot
study, add-on to gabapentin
treatment regimens
49 6.3 (BPI)a 2.5
(24 h
on)
2 weeks Pain intensity and pain relief scores
improved (p\0.0001)a. Quality
of life improved for all BPI
domains (p\0.05)
Argoff et al. [75]. Prospective,




2 weeks Improvement in all composite
measures of the NPS (p\0.001)














4 weeks Treatment response (reductions in
pain intensity and allodynia
severity) comparable in both
groups, greater improvements in
quality of life (EQ-5D) in
patients receiving lidocaine
plaster
All data are expressed as the mean unless otherwise stated. For studies with a control group, only lidocaine data are shown
BPI brief pain inventory, EQ-5D EuroQol-5 dimension QoL index, N/A not available, NPS neuropathic pain scale, NRS
numerical rating scale
a Includes data from patients with postherpetic neuralgia and low back pain
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patients rated the quality of post-surgical pain
control significantly better with the lidocaine
plaster than with placebo (p = 0.037). They also
reported significantly less interference with
walking, deep breathing, and mood (p\0.05)
[79]. The retrospective study by Saber et al.
involved placement of the 5%
lidocaine-medicated plaster on the anterior
abdominal wall for 3 days following
laparoscopic ventral herniorrhaphy [80]. The
mean time to discharge was shorter in patients
receiving the plaster than in controls (1.2 vs.
2.5 days; not statistically significant;
p = 0.1421), but the mean pain score was
significantly lower (p = 0.0067, see Table 2).
Two weeks after surgery, a difference in mean
pain score was still apparent (2.00 vs. 2.93), but
was no longer statistically significant
(p = 0.1245) [80]. A randomized,
placebo-controlled trial in patients undergoing
robotic thoracic surgery concluded that 5%
lidocaine plasters did not influence acute or
persistent incisional pain, but pain scores in this
study were low in both treatment groups [81]. A
meta-analysis of efficacy of the plaster in acute
pain management reported similar findings, but
was limited by the inclusion of only five studies,
potential bias from unblinded studies, clinical
heterogeneity, and incomplete data regarding
adjunct analgesics [82].
The use of 5% lidocaine-medicated plasters
to treat chronic post-surgical and
post-traumatic neuropathic pain has been
evaluated in a number of studies.
Post-surgical/post-traumatic neuropathic
chronic cutaneous pain (PNCCP) may be a
side effect of any incision of the skin following
a surgical procedure or trauma [78]. One
open-label, non-randomized, prospective case
series of 40 patients with PNCCP reported
reductions in mean pain intensity (Visual
Analogue Scale or VAS) and mean Leeds
Assessment of Neuropathic Symptoms and
Signs (LANSS) scores of 36.1 and 30.9%,
respectively, after 12 weeks’ treatment with the
lidocaine plaster (Table 2) [78]. Almost half
(47.5%) of the patients experienced a C50%
reduction in pain [78]. A 2011 retrospective
review evaluated 58 case reports of patients who
had been treated with the lidocaine plaster for
PNCCP following surgical and non-surgical
trauma [83]. Clinical Global Impression of
Change (CGIC) scores of ‘Much Improvement’
or ‘Very Much Improvement’ were recorded for
76% of the patients (Table 2), including all the
patients (17%) who had received the plaster as
monotherapy [83]. However, lidocaine plasters
did not reduce combined resting and dynamic
pain ratings in 21 patients with severe,
persistent inguinal postherniorrhaphy pain
compared with placebo [84].
A prospective, open-label, clinical case series
has investigated use of the 5%
lidocaine-medicated plaster to treat
neuropathic pain in scars resulting from burns,
skin de-gloving or orthopedic surgery (Table 2)
[58]. The mean duration of pain before starting
treatment with the lidocaine plaster was
9.7 months, and the mean duration of topical
treatment was 13.9 weeks. At the end of this
period, the mean NRS score had decreased by
58.2% and reductions of C50% were reported by
69% of the patients [58]. Significant functional
improvement was recorded by 58.6% of the
patients, indicating fewer problems with
walking, sleeping and normal daily activities
[58]. Most notably, however, the mean size of
the painful area was reduced by 72.4%—similar
to that reported by Casale et al. in patients with
PHN—and 86.2% of the patients experienced a
reduction of C50% [58]. A later study by some
of the same investigators evaluated the
lidocaine plaster in the treatment of LNP
following traumatic injury to peripheral
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nerves, over a mean period of 19.5 weeks
(Table 2) [59]. The results were similar; the
mean NRS score decreased by 58.2% and the
mean size of the painful area decreased by
87.6%, with 94.7% of the patients experiencing
a reduction in size of C50% [59]. No local or
systemic adverse reactions were recorded in
either of these studies [58, 59].
The retrospective case series published by
Likar et al. in 2015 includes seven patients with
post-surgical/post-traumatic pain, who were
observed over a period of 6 months (Table 2)
[85]. All pain parameters were measured on an
11-point Likert scale (0 = not present to
10 = worst possible state). At the end of the
observation period, the mean pain intensity
score had decreased by 78%, from 8.6 at
baseline to 1.9, and no adverse events were
considered to be related to the 5%
lidocaine-medicated plaster [85]. These
findings are well in agreement with previous
studies and case series in patients with
post-surgical/post-traumatic pain [52].
Wide-Ranging Reviews
In order to provide an overview of the efficacy
and safety of the 5% lidocaine-medicated
plaster in treating LNP, in 2012 Mick and
Correa-Illanes reviewed 60 clinical studies
(randomized, controlled or open-label with
well-described methodology) dating back to
1960, as well as case reports and
pharmacological studies [52]. Most related to
PHN, DN or post-surgical/post-traumatic/scar
pain, but other LNP conditions were also
included, such as idiopathic sensory
polyneuropathy, complex regional pain
syndrome, and carpal tunnel syndrome
sequelae. In the majority of studies, the
lidocaine plaster was added to the existing
analgesic regimen. The lidocaine plaster was
found to be efficacious in both short-term and
long-term controlled, randomized or open-label
studies [52]. Patients’ quality of life markedly
improved in a variety of neuropathic pain
conditions and pain relief was sustained over
long-term treatment. The very low systemic
exposure after administration meant that the
plaster was very well tolerated, the most
common ADRs being mild to moderate
application site reactions [52]. Much of the
evidence examined (in conditions other than
PHN) was based on open-label studies with
small sample sizes, or case reports, and the
authors called for more controlled trials, but
considered the lidocaine plaster may be a useful
option for managing LNP, particularly in view
of its excellent safety profile [52].
A later reappraisal of the clinical evidence for
using the 5% medicated lidocaine plaster
retrieved all relevant efficacy and safety studies
(randomized, controlled, or open-label with
well-described methodology), case reports and
observational studies from a PubMed literature
search covering the period from 1960 to
September 30, 2015 [2]. Additional references
were identified from published articles and the
inclusion of studies was based on the
methodology used, with large, well-controlled
trials using appropriate statistical techniques
being preferred [2]. Again, a diverse range of
LNP conditions was covered in addition to PHN,
DN, and post-surgical/post-traumatic/scar pain;
these included myofascial pain syndrome,
cervical radiculopathy, trigeminal neuralgia,
and orofacial pain. Analysis of this large
volume of data suggested that the lidocaine
plaster is an effective and well-tolerated
treatment option in patients with LNP, and
the authors noted that numerous systematic
reviews included it as a first-line option for
treating PHN [2]. It was found to be easy to use,
improves patients’ quality of life, has a good
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tolerability profile and is associated with both a
lack of systemic ADRs and a low potential for
drug–drug interactions [2]. Thus, it was
concluded that the lidocaine plaster would
appear to be indicated as the first step in the
treatment of LNP either as a single agent or as a
component of multimodal therapy [2].
DISCUSSION
There is mounting evidence of the efficacy of
the 5% lidocaine-medicated plaster in studies
conducted in everyday clinical practice, which
represents a considerable proportion of actual
usage. Many of these studies suggest using the
lidocaine plaster as a first-line treatment for
LNP, but this is not always reflected in national
and international guidelines. There are various
reasons for this.
Guidelines for analgesic agents are generally
based on the results of randomized,
double-blind, placebo-controlled clinical trials
using the NNT for a defined level of pain relief
as the measure of efficacy. In a review of 105
randomized, double-blind, placebo-controlled
trials in patients with neuropathic pain, for
example, the 5% lidocaine-medicated plaster
had an NNT of 4.4, comparable to
antidepressants (1.2–6.9) and anticonvulsants
(1.4–7.4) [36].
However, many trials of the lidocaine plaster
used the time to withdrawal to indicate efficacy,
for which it was not possible to calculate NNTs.
These trials were therefore excluded when
drawing up the guidelines, thereby weakening
the body of evidence for the 5%
lidocaine-medicated plaster.
Furthermore, the value of NNTs in the
development of guidelines is limited on
several counts [2]. Firstly, reliable NNT data
from multiple studies can only be obtained
where these are parallel-designed,
placebo-controlled studies with comparable
inclusion and exclusion criteria [2, 86]. The
statistical design of the lidocaine plaster trials
varied from study to study, as did the maximum
dose—from less than one plaster to three
plasters. Secondly, NNTs are primarily derived
from patients’ VAS evaluations of pain, which
researchers now recognize may be
inappropriate, so that other criteria (patient
global impression of pain improvement,
psychosocial functioning, activities of daily
living, gait, quality of life) are used to provide
a more complete assessment of analgesic
efficacy [2]. Therefore, any NNT data would
have been of limited benefit. Further limitations
are that non-placebo-controlled trials were
excluded and efficacy was generally based on a
one-dimensional measure of pain intensity or
pain relief, so a statistically significant
advantage could not necessarily be translated
into a clinically relevant benefit.
In the case of the 2015 NeuPSIG guidelines,
another consideration is that studies with an
enriched enrolment design were analyzed
separately, despite the fact that these can be
useful in determining the efficacy of a
medication compared to placebo; there
appears to be no difference between enriched
and non-enriched studies when measuring this
parameter [87, 88]. A meta-analysis of 26
enriched enrolment, randomized withdrawal
(EERW) trials in over 5000 patients with
chronic non-cancer pain concluded that these
trials ‘if properly designed, conducted, and
reported, are entirely appropriate in the
context of chronic pain for explaining
whether a treatment is efficacious, and for
pragmatically supporting decisions over its
use’ [88]. Some authors have even contended
that the available guidelines have very little
clinical application to daily practice because
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multimodal therapy is widely considered the
treatment of choice for LNP, but evidence-based
data on this approach is lacking [89].
The excellent tolerability of the 5%
lidocaine-medicated plaster, its lack of ADRs,
and low potential for drug–drug interactions,
are widely recognized. This is a particularly
important consideration when treating elderly
and/or frail patients, or those receiving multiple
medications. Both the EFNS and 2015 NeuPSIG
guidelines recognize these benefits, stipulating
that the lidocaine plaster may be considered a
first-line option for these patients [13, 56].
Furthermore, its safety profile and ease of use
can significantly increase patients’ adherence to
chronic treatment, with consequent benefits on
efficacy and quality of life [33].
Taking a wider perspective, a number of
studies have recorded significantly better
quality of life (QoL) scores following
commencement of treatment with the
lidocaine plaster. For example, in one large,
open-label effectiveness study in patients with
PHN, the mean pain interference with QoL
significantly decreased in all domains of the
Brief Pain Inventory Short Form (general
activity, mood, walking, working, relations,
sleeping, enjoyment) after 7, 14, and 28 days’
treatment (p\0.0001) [70]. Similarly, when 56
patients with painful diabetic polyneuropathy
were treated for 3 weeks (up to four plasters/day
for 18 h), significant improvements were seen in
sleep quality, interference of pain with daily
activities, depression, and mood [90]. More
recently, a 2012 study used the QoL
Impairment by Pain Inventory (QLIP) to
evaluate the perceptions of over 900 patients
with chronic neuropathic pain who received
treatment with the lidocaine plaster [91]. QLIP
measures well-being, sleep, pain, impairments,
and mood, the maximum score of 40 points
reflecting minimal interference with daily life.
Over the 12 weeks of the study, the mean QLIP
score increased from 13.7 to 35.2 [91].
Allodynia is often a prominent feature of
LNP, and is usually considered to be one of
the most distressing and debilitating
symptoms of PHN [92, 93]. Therefore, one
contributory factor to the improved QoL
scores is likely to be the reduction in the
area of allodynia—typically more than 50%
[59, 60]—produced by treatment with the
lidocaine plaster. Reducing the painful area,
which can increase tolerance of bathing and
contact with clothing, is therefore a justifiable
treatment goal for this medication. When the
painful area is on the sole of the foot—
limiting mobility—or on the palm of the
hand, this advantage of the topical route
and the 5% lidocaine-medicated plaster over
systemic medications assumes even greater
importance [58].
CONCLUSIONS
The 5% lidocaine-medicated plaster has
demonstrated efficacy in a variety of LNP
conditions and in long-term treatment, has an
excellent safety profile, does not require dose
titration, and can easily be applied by the
patient. On these grounds, and accepting the
need for additional controlled clinical trials, it
should be strongly recommended for treating
LNP—either as one component of a multimodal
approach or as monotherapy.
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